医学
阿扎胞苷
内科学
骨髓增生异常综合症
血红蛋白
生活质量(医疗保健)
髓系白血病
胃肠病学
肿瘤科
骨髓
生物化学
基因表达
化学
护理部
DNA甲基化
基因
作者
Zoe McQuilten,Ljoudmila Busija,John F. Seymour,Simon Stanworth,Erica M. Wood,Melita Kenealy,Robert Weinkove,NULL AUTHOR_ID
标识
DOI:10.1080/10428194.2021.2012664
摘要
Myelodysplastic syndromes (MDS) have a major impact on quality of life (QoL). We performed a post hoc analysis of two multicenter trials of azacitidine-based disease-modifying therapy for patients with MDS and low blast count acute myeloid leukemia (AML), to identify factors associated with QoL. 231 patients were included (median age 70 years). At baseline, higher initial hemoglobin, but not neutrophil or platelet count, was associated with better global QoL and physical function (p < 0.001 and p = 0.001, respectively). During therapy, increase in hemoglobin was associated with improvement in QoL and physical function (p = 0.005 and p < 0.001, respectively). Lower initial hemoglobin was associated with higher dyspnea and fatigue scores (p < 0.001 and p = 0.001, respectively), and hemoglobin response was associated with improvement in dyspnea and fatigue (p < 0.001 for each). In patients with MDS and low blast count AML, hemoglobin level was strongly correlated with global QoL, physical functioning, dyspnea and fatigue, both before and during azacitidine-based therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI